Nkgen Biotech Inc NKGN

Healthcare Biotechnology

NKGen Biotech, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapeutics. Its product candidates are based on a manufacturing and cryopreservation process, which produces SuperNK (SNK) cells. SNK cells can be produced in large quantities and cryopreserved, while maintaining high levels of cytotoxicity and activating receptor expression after thawing and reconstitution. It is developing SNK01, an autologous natural killer (NK) cell therapy, for the treatment of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD). Its autologous NK cell therapy candidate has clinical trials in several therapeutic areas, including oncology and neurodegeneration. SNK02 is its allogeneic NK cell product candidate. It is conducting clinical trials with its SNK cell therapy in patients with neurodegenerative disease (SNK01) and cancer (SNK02).

NDAQ:NKGN - Post by User

Nkgen Biotech Inc > NKGN....early a.m runner on NR....Caveat Emptor imho ; )

<< Previous

Bullboard Posts

Next >>

Post by Iseneschalon Jul 18, 2024 9:10am

49 Views

Post# 36138052

NKGN....early a.m runner on NR....Caveat Emptor imho ; )

Be a chaser and your going to get your face ripped off....P.O set up!!!

https://www.sec.gov/Archives/edgar/data/1845459/000121390024060562/ea0204651-06.htm

Currently $1.25 in the PM opening

<< Previous

Bullboard Posts

Next >>

Gold vs. bitcoin, where should you invest?